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Background: It has been demonstrated that glucose transporter (GLUT1) deficiency in a mouse model causes a
diminished cerebral lipid synthesis. This deficient lipid biosynthesis could contribute to secondary CoQ deficiency.
We report here, for the first time an association between GLUT1 and coenzyme Q10 deficiency in a pediatric patient.
Case presentation: We report a 15 year-old girl with truncal ataxia, nystagmus, dysarthria and myoclonic epilepsy
as the main clinical features. Blood lactate and alanine values were increased, and coenzyme Q10 was deficient both
in muscle and fibroblasts. Coenzyme Q10 supplementation was initiated, improving ataxia and nystagmus. Since
dysarthria and myoclonic epilepsy persisted, a lumbar puncture was performed at 12 years of age disclosing
diminished cerebrospinal glucose concentrations. Diagnosis of GLUT1 deficiency was confirmed by the presence
of a de novo heterozygous variant (c.18+2T>G) in the SLC2A1 gene. No mutations were found in coenzyme Q10
biosynthesis related genes. A ketogenic diet was initiated with an excellent clinical outcome. Functional studies in
fibroblasts supported the potential pathogenicity of coenzyme Q10 deficiency in GLUT1 mutant cells when compared
with controls.
Conclusion: Our results suggest that coenzyme Q10 deficiency might be a new factor in the pathogenesis of G1D,
although this deficiency needs to be confirmed in a larger group of G1D patients as well as in animal models.
Although ketogenic diet seems to correct the clinical consequences of CoQ deficiency, adjuvant treatment with
CoQ could be trialled in this condition if our findings are confirmed in further G1D patients.
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GLUT1 deficiency syndrome (G1D) most often causes
infantile-onset refractory epilepsy, cognitive impairment
and motor abnormalities (ataxia, dystonia, chorea or dys-
kinesia) [1-4]. The main pathophysiological mechanism of
the disease is associated with impaired glucose transport
across the blood brain barrier and through astrocyte cell
membranes that are haploinsufficient in the GLUT1 glu-
cose carrier encoded by the SLC2A1 gene [5,6]. However* Correspondence: rartuch@hsjdbcn.org
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unless otherwise stated.it is unclear how decreased glucose flux leads to the mani-
festations of the disorder.
G1D is a partially treatable condition with ketogenic
diet (KD), which can replace glucose for acetyl-CoA gen-
eration [7,8]. Energy failure has been proven in G1D
astrocytes, while tricarboxilyc acid abundance in the brain
of G1D mouse model is normal. These findings support
the complementary or alternative view that additional
mechanisms participate in disease pathogenesis, placing
new emphasis on G1D as a glial disease [9]. This conten-
tion is highlighted by the preliminary therapeutic efficacy
of triheptanoin, a dietary supplement with the potential to
stimulate cerebral anabolism and energy delivery [10].
Coenzyme Q10 (CoQ) is a lipidic electron carrier in
the mitochondrial respiratory chain (MRC). One of the
essential substrates for CoQ generation is acetyl-CoALtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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pathway are associated with different clinical phenotypes,
being cerebellar ataxia the most common one [11]. How-
ever, “secondary” CoQ deficiency is also characteristic of
other diseases, since CoQ biosynthesis involves an intri-
cate, broad set of reactions that may be potentially im-
pacted by “primary” disturbance of several biochemical
processes [12].
Our aim is to describe, for the first time a relevant
association between G1D and CoQ deficiency. Clinical,
biochemical, molecular and therapeutic observations con-
stitute the basis of this association.
Case presentation
The proband is a 15-years old girl with an unremarkable
family history. At 18 months old she manifested no ambu-
lation, and by 3 years old she had developed ataxia and
epilepsy with normal neuroimaging. At 5 years old clinical
examination showed axial hypotonia, truncal ataxia, limb
dysmetria and hyperreflexia. Paroxysmal nystagmus, sac-
cadization of visual pursuit and dysarthria were observed.
The patient also exhibited intellectual disability (IQ = 54).
Biochemical analyses in blood disclosed elevated lactate
in 3 separate occasions and elevated alanine in 12 de-
terminations (Table 1). Muscle and skin biopsies were




Lactate 1.8-2.6 (2.2) 0.5-1.7 mmol/L
Alanine 300-691 (560) 150-270 μmol/L
Cholesterol 4.0 < 5.2 mmol/L
CoQ (baseline) 0.33 0.45-1.1 μmol/L
CoQ (after treatment) 3.9-7.8 (5.5) 0.45-1.1 μmol/L
Cerebrospinal fluid
Glucose 1.9 2.2-3.4 mmol/L
Lactate 1.07 1.1-2.2 mmol/L
Muscle biopsy
CoQ content 76 115-450 nmol/g protein
Complex I + III* 149 107-560 mU/citrate
synthase U





78 100-150 nmol/g protein
CoQ content (incubated
with galactose)
123 100-150 nmol/g protein
Patient results from blood are expressed as range (median).
*Complex I + III: NADH:cytochrome C oxidoreductase. Complex II + III: succinate:
cytochrome C oxidoreductase.disorders. CoQ deficiency was identified both in muscle
and fibroblasts (see Results). Because of this finding, CoQ
supplementation (orally administered at 30 mg/Kg/day)
was initiated. Ataxia improved dramatically after 6 months
of therapy, and, upon reassessment after 4 years of CoQ
treatment, ambulation remained essentially normal, with
a mild residual reduction in velocity. Her nystagmus
had also disappeared and her visual pursuit had normal-
ized [13]. However, mild dysmetria, dysarthria, myoclonic
epilepsy and intellectual disability (perhaps refractory to
CoQ), were present. During CoQ therapy, concomitant
treatment with valproate and ethosuximide was given
to control myoclonic epilepsy. No noticeable side-effects
were observed when antiepileptic doses were raised to
maintain therapeutic levels along the evolution of the
disease due to the patient increasing weight. In order
to further investigate these manifestations, a lumbar
puncture was performed at 12 years of age, revealing
diminished cerebrospinal glucose concentrations (Table 1).
Plasma glucose concentration was normal. Diagnosis of
GLUT1 deficiency (G1D) was established and a ketogenic
diet (4:1 ratio, containing medium chain triglyceride oil)
was initiated (CoQ treatment was then discontinued).
Written informed consent was obtained from the parents.
The study was approved by the Ethical Committee of our
Hospital.
Laboratory investigations
Muscle and skin biopsies were collected, stored and
cultured following previously reported procedures [14].
CoQ content was analyzed by HPLC with electrochemical
detection, and MRC enzyme activities by spectrophotom-
etry as reported [14].
Functional studies in fibroblasts: Human Dermal Fibro-
blasts (HDF) were grown in Dulbecco’s modified essential
medium as previously reported [15]. Cells were grown
with 1 g/L of either glucose or galactose from plating and
throughout the entire duration of the observation period.
Mycoplasma testing was negative. Also normal and G1D
fibroblasts were supplemented with 30 μmol/L CoQ.
Growth rate was analyzed as indicated [15].
Molecular analysis of genomic DNA (gDNA) isolated
from blood included Sanger sequencing of 12 genes invol-
ved in CoQ biosynthesis (ADCK3, ADCK4, PDSS1, PDSS2,
COQ2, COQ3, COQ4, COQ5, COQ6, COQ9, CQ10A and
COQ10B), in addition to the SLC2A1 gene, which encodes
for GLUT1 transporter. In silico mutation analysis was
done by the Mutation Taster software.
Total RNA was isolated from control and patient’s fibro-
blast cultures with RNeasy Fibrous Tissue mini kit (Qiagen,
Hilden, Germany). 1 μg of RNA was retro-transcribed with
GoTaq® Probe 2-Step for RT-PCR (Promega, Wisconsin,
USA) to obtain cDNA. SLC2A1 mRNA transcripts were
studied on cDNA through PCR amplification with specific
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by direct sequencing.
Results
Muscle and fibroblasts CoQ content was decreased
(Table 1). Functional studies of cell viability in culture with
either glucose or galactose are illustrated in Figure 1A.
The GLUT1 mutant cell line cultured in the presence of
glucose displayed significantly decreased growth rate
when compared with cultures grown in medium with gal-
actose. Furthermore, the control cell line growth rate was
significantly greater than those observed for the GLUT1
mutant line when cultured in glucose-containing medium.
CoQ content was increased in GLUT1 mutant fibroblasts
after 10 days growth in galactose (Table 1) while it re-
mained unchanged in fibroblasts incubated in glucose
media for the same length of time. CoQ supplementation
of patient’s fibroblasts for one week induced an increase
of 37% cell growth rate while the growth rate of control
cells with the same treatment only increased by 15%
(Figure 1B).
Sequencing of CoQ-related genes disclosed no known
pathogenic variants. G1D was established after the de-
tection of a new heterozygous variant (c.18+2T>G) in
the first intron of the SLC2A1 gene (Figure 2A). The
variant was not present in 200 studied alleles of Spanish
ancestry. Conservation of the nucleotide position was
high according to Phylophen scores and splice prediction







































Figure 1 Growth of GLUT1 fibroblast mutant cell line compared with
seeded (2.000 cells/plate) and incubated with either glucose or galactose. B
with or without 30 μM CoQ.(data not shown). The cDNA region encompassing the
genomic DNA mutation was amplified to detect a possible
altered mRNA transcript in the patient. The PCR product
did not show alternate amplification bands other than the
control one (Figure 2B). Patient’s sample direct sequen-
cing showed only the wild type transcript, lacking any hint
of an aberrant transcript consequence of the intronic mu-
tation identified in gDNA. Concurrently, patient carried a
heterozygous SNP (rs1385129) located in exon 2, initially
identified in gDNA (both alleles (T/C) were represented).
We analyzed this SNP on the cDNA sequence (Figure 2C),
and only one allele was present (C), pointing out that half
doses of wild type mRNA was not present. Since the vari-
ant is located in the splice donor site and we only detected
one allele of rs1385129 in the patient’s cDNA, down-
stream of c.18+2T>G, we hypothesize that splicing of the
SLC2A1 mRNA could be altered.
Therapeutic interventions
After initiation of a ketogenic diet at 14 years old, dysarth-
ria was controlled. At this age and prior to KD, mioclonic
jerks with absences were present and EEG disclosed slow
basal rhythm (alpha: 7–8 Hz) and generalized spike-wave
discharges at 2.5 HZ, suggesting atypical absences. At that
moment, patient was treated with valproate and ethosu-
ximide. Epilepsy was totally controlled after 3 months of
KD, and EEG disclosed normal results, except for slow
basal activity. Antiepileptic treatment was progressively


















medium supplemented with 30
µM CoQ10
control Human Dermal Fibroblasts (HDF). A). Both cells were
). Both cells were seeded (50.000 cells/plate) and grown for one week
Figure 2 Genetic analysis. A- Electropherogram containing genomic SLC2A1 DNA mutation in a case with GLUT1 deficiency. B- 3% agarose gel
showing a 219 base pairs PCR amplification of SLC2A1 cDNA region enconmpassing the spling mutation. C (control) and P (patient). C- Patient’s
electropherograms showing a synonymous polymorphism (rs1385129, see dbSNP database) in heterozygous state in gDNA and in hemizygous
state in cDNA.
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appear during KD therapy. Plasma CoQ levels were nor-
mal after initiation of a KD (0.58 μmol/L; reference values
shown in Table 1).
Discussion
We present for the first time, the identification of CoQ
deficiency in a patient with G1D. Our clinical and bio-
chemical observations warrant further discussion be-
cause of their potential pathophysiological and therapeutic
implications.
Concerning the pathophysiology of G1D, Marin-
Valencia et al. [9], demonstrated in a G1D mouse model
a diminished cerebral lipid synthesis. Importantly, this
deficient lipid biosynthesis could contribute to secondary
CoQ deficiency. The muscle CoQ deficiency detected in
our patient was mild, and this would explain that MRC
enzyme activities were low-normal. However, we interro-
gated mitochondrial function due to the conjunction of
the clinical findings and the consistent hyperlactacide-
mia and hyperalaninemia observed in our case. The ex-
periments conducted in fibroblasts confirmed the CoQ
deficiency, in agreement with its potential role in the
pathophysiology of G1D [11]. Especially relevant were
the differences of growth observed between fibroblasts
cultured with either glucose or galactose and the recov-
ery of CoQ in galactose growth. Glucose transport was
impaired in the mutant line, but not galactose influx,
which is able in turn to promote CoQ biosynthesis[15]. The human genome encodes for fourteen GLUT
proteins that cooperate to transport different substrates
other than glucose [16].
The normalization of growth of G1D cells after the
incubation of fibroblasts with CoQ suggests the potential
benefit of this coadjuvant therapy for G1D patients,
which deserves further investigations. Although the mu-
tation detected in SLC2A1 is compatible with the com-
mon G1D phenotype, we cannot rule out the existence
of mutations in other genes involved in CoQ metabolism
given the fact that the CoQ metabolic pathway is not
well understood.
The observed clinical improvement after CoQ supple-
mentation in our patient supports these statements given
that the most severe cerebellar manifestations proved
amenable to CoQ therapy [13]. The simplest interpret-
ation of our clinical observations is provided by the notion
that the cerebellum is an extremely sensitive organ to oxi-
dative stress and energy metabolic disorders, consistent
with the near-universal demonstration of cerebellar mani-
festations even in cases of mild CoQ deficiency [11,13].
Once a ketogenic diet was initiated, the clinical outcome
was excellent, with a complete cessation of epilepsy
and other signs. We did not simultaneously treat the
patient with CoQ and the ketogenic diet in order to
separately elucidate the individual effects of both in-
terventions. It is possible that a ketogenic diet causes a
recovery in lipid biosynthesis that favorably impacts CoQ
abundance.
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CoQ deficiency might be a new factor in the pathogenesis
of G1D, although CoQ deficiency needs to be confirmed
in a larger group of G1D patients as well as in animal
models. Although KD seems to correct the clinical conse-
quences of CoQ deficiency, adjuvant treatment with CoQ
could be trialled in this condition if our findings are con-
firmed in further G1D patients. Furthermore, since mo-
lecular basis of CoQ deficiency syndrome remains elusive
in most cases, the investigation of GLUT1 deficiency is
advisable in cases presenting ataxia and epilepsy.
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